Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct

Solid lipid nanoparticles (SLNs) were prepared with a combination of homolipid from goat (goat fat) and phospholipid, and evaluated for diclofenac sodium (DNa) delivery to the eye using bio-engineered human cornea, produced from immortalized human corneal endothelial cells (HENC), stromal fibroblast...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2008-05, Vol.355 (1), p.307-313
Main Authors: Attama, Anthony A., Reichl, Stephan, Müller-Goymann, Christel C.
Format: Article
Language:English
Subjects:
Algorithms
Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
Biological and medical sciences
Biological Transport, Active
Calorimetry, Differential Scanning
Chemistry, Pharmaceutical
Chromatography, High Pressure Liquid
Cornea - metabolism
Diclofenac - administration & dosage
Diclofenac sodium
Drug Compounding
Drug permeation
Eye - metabolism
General pharmacology
Human cornea construct
Humans
Lipids
Medical sciences
Nanoparticles
Ocular drug delivery
Particle Size
Permeability
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Solid lipid nanoparticles
Solubility
Surface modification
Tissue Engineering
X-Ray Diffraction
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Solid lipid nanoparticles (SLNs) were prepared with a combination of homolipid from goat (goat fat) and phospholipid, and evaluated for diclofenac sodium (DNa) delivery to the eye using bio-engineered human cornea, produced from immortalized human corneal endothelial cells (HENC), stromal fibroblasts and epithelial cells CEPI 17 CL 4. Encapsulation efficiency was high and sustained release of DNa and high permeation through the bio-engineered cornea were achieved. Results obtained in this work showed that permeation of DNa through the cornea construct was improved by formulation as SLN modified with phospholipid.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2007.12.007